Interacciones de Budesonida

Budesonida (Pulmicort, Entocort, Uceris), corticosteroide, tiene 343 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 30; moderadas: 234; leves: 79; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Qué aspecto tiene Budesonida

Todas las versiones (8)
Budesonida, tableta de 9 mg: blanca, redonda, 10 mm, con la inscripción MX9.
MX9
9 mg · blanca · redonda · 10 mm
Santarus
Budesonida, cápsula de 4 mg: blanca, 19 mm, con la inscripción CAL10 en una cara y 4MG en la otra.
CAL10 / 4MG
4 mg · blanca · cápsula · 19 mm
Calliditas Therapeutics AB
Budesonida, cápsula de 3 mg: naranja y blanca, 19 mm, con la inscripción 720.
720
3 mg · naranja y blanca · cápsula · 19 mm
Zydus Pharmaceuticals
Budesonida, cápsula de 3 mg: gris y roja, 19 mm, con la inscripción AMNEAL en una cara y 778 en la otra.
AMNEAL / 778
3 mg · gris y roja · cápsula · 19 mm
Amneal Pharmaceuticals of…

Representaciones generadas a partir de los listados de productos de las etiquetas de la FDA: color, forma, tamaño e inscripción. 8 versiones documentadas de 11 etiquetadores.

Interacciones según la etiqueta

Interacciones graves (30)

  • Abirateronainhibidor de CYP2D6Grave

    At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (etiqueta de Abiraterona, Advertencias y precauciones)

  • AdalimumabinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

  • AdrenalinasimpaticomiméticoGrave

    …Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (etiqueta de Adrenalina, Interacciones medicamentosas)

  • Arformoterolagonista beta-adrenérgicoGrave

    Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (etiqueta de Arformoterol, Contraindicaciones)

  • AtazanavirantirretroviralGrave

    Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (etiqueta de Atazanavir, Interacciones medicamentosas)

  • Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (etiqueta de Axitinib, Advertencias y precauciones)

  • Baricitinibinhibidor de JAKGrave

    Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Baricitinib, Advertencia en recuadro)

  • Budesonida y formoterolcorticosteroideGrave

    Paradoxical Bronchospasm and Upper Airway Symptoms As with other inhaled medications, budesonide and formoterol fumarate dihydrate can produce paradoxical bronchospasm, which may be life threatening. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

  • Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (etiqueta de Docetaxel, Advertencias y precauciones)

  • …(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (etiqueta de Emtricitabina, rilpivirina y tenofovir, Contraindicaciones)

  • EtanerceptinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Etanercept, Advertencia en recuadro)

  • Formoterolagonista beta-adrenérgicoGrave

    Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (etiqueta de Formoterol, Contraindicaciones)

  • FosamprenavirantirretroviralGrave

    Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (etiqueta de Fosamprenavir, Interacciones medicamentosas)

  • InfliximabinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Infliximab, Advertencia en recuadro)

  • Ketoconazolantifúngico azólicoGrave

    Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (etiqueta de Ketoconazol, Interacciones medicamentosas)

  • LovastatinaestatinaGrave

    Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (etiqueta de Lovastatina, Contraindicaciones)

  • Mifepristonainhibidor de CYP3A4Grave

    WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (etiqueta de Mifepristona, Advertencia en recuadro)

  • Mitotanoinductor de CYP3A4Grave

    If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (etiqueta de Mitotano, Advertencia en recuadro)

  • Moexiprilinhibidor de la ECAGrave

    None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (etiqueta de Moexipril, Advertencias)

  • RilpivirinaantirretroviralGrave

    Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (etiqueta de Rilpivirina, Contraindicaciones)

  • Salmeterolagonista beta-adrenérgicoGrave

    WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (etiqueta de Salmeterol, Advertencia en recuadro)

  • SirolimusinmunosupresorGrave

    In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (etiqueta de Sirolimus, Advertencias y precauciones)

  • Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (etiqueta de Somatropina, Interacciones medicamentosas)

  • TocilizumabinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Tocilizumab, Advertencia en recuadro)

  • TofacitinibinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Tofacitinib, Advertencia en recuadro)

  • Trandolaprilinhibidor de la ECAGrave

    Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (etiqueta de Trandolapril, Advertencias)

  • TretinoínaretinoideGrave

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etiqueta de Tretinoína, Advertencia en recuadro)

  • Trióxido de arsénicofármaco que prolonga el intervalo QTGrave

    If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (etiqueta de Trióxido de arsénico, Advertencia en recuadro)

  • Umeclidinio y vilanterolanticolinérgicoGrave

    • use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (etiqueta de Umeclidinio y vilanterol, Contraindicaciones)

  • UpadacitinibinmunosupresorGrave

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Interacciones moderadas (234)

  • The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (etiqueta de Ácido acetilsalicílico, Advertencias)

  • Ácido mefenámicoAINEModerada

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (etiqueta de Ácido mefenámico, Advertencias y precauciones)

  • Ácido valproicoanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • Ácido zoledrónicobisfosfonatoModerada

    A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etiqueta de Ácido zoledrónico, Advertencias y precauciones)

  • AclidinioanticolinérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • AfatinibModerada

    Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (etiqueta de Afatinib, Advertencias y precauciones)

  • AlbendazolModerada

    Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (etiqueta de Albendazol, Advertencias y precauciones)

  • AlemtuzumabinmunosupresorModerada

    Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (etiqueta de Alemtuzumab, Advertencias y precauciones)

  • AlendronatobisfosfonatoModerada

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (etiqueta de Alendronato, Advertencias y precauciones)

  • AliskirenoantihipertensivoModerada

    Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (etiqueta de Aliskireno, Advertencias y precauciones)

  • Alogliptina y metforminainhibidor de la DPP-4Moderada

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (etiqueta de Alogliptina y metformina, Interacciones medicamentosas)

  • AlpelisibModerada

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

  • AminofilinametilxantinaModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • AmiodaronaantiarrítmicoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Anfotericina BantifúngicoModerada

    Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (etiqueta de Anfotericina B, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Moderada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • BeclometasonacorticosteroideModerada

    Lung function (FEV 1 or PEF), beta‑agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (etiqueta de Beclometasona, Advertencias y precauciones)

  • Belladona y opioopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Belladona y opio, Advertencias y precauciones)

  • BendamustinaModerada

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

  • BenralizumabModerada

    • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (etiqueta de Benralizumab, Advertencias y precauciones)

  • Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

  • BrivaracetamanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • BuprenorfinaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Buprenorfina, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Buprenorfina y naloxona, Advertencias y precauciones)

  • BupropiónantidepresivoModerada

    …risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (etiqueta de Bupropión, Advertencias y precauciones)

  • In patients receiving concomitant corticosteroids and chronic use of aspirin, withdrawal of corticosteroids may result in salicylism because corticosteroids enhance renal clearance of salicylates and their withdrawal is followed by return to normal rates of renal clearance. (etiqueta de Butalbital, ácido acetilsalicílico y cafeína, Interacciones medicamentosas)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Butalbital, paracetamol, cafeína y codeína, Advertencias y precauciones)

  • ButorfanolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Butorfanol, Advertencias)

  • Cannabidiol (con receta)anticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • CarbamazepinaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • CefoxitinacefalosporinaModerada

    High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (etiqueta de Cefoxitina, Advertencias y precauciones)

  • CelecoxibAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Celecoxib, Advertencias y precauciones)

  • CenobamatoanticonvulsivoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • CiclosporinainmunosupresorModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Cimetidinaantagonista H2Moderada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • CiprofloxacinofluoroquinolonaModerada

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Ciprofloxacino, Advertencias y precauciones)

  • CitarabinaantimetabolitoModerada

    These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (etiqueta de Citarabina, Advertencias)

  • CladribinaantimetabolitoModerada

    Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etiqueta de Cladribina, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • ClobazambenzodiazepinaModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • ClonazepambenzodiazepinaModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • Cocaínaanestésico localModerada

    Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (etiqueta de Cocaína, Interacciones medicamentosas)

  • CodeínaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Codeína, Advertencias y precauciones)

  • DaptomicinaantibióticoModerada

    Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (etiqueta de Daptomicina, Advertencias y precauciones)

  • DarunavirantirretroviralModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Darunavir y cobicistatantirretroviralModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Deferasiroxsuplemento de hierroModerada

    Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive… (etiqueta de Deferasirox, Interacciones medicamentosas)

  • DenosumabModerada

    Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etiqueta de Denosumab, Advertencias y precauciones)

  • Desogestrel y etinilestradiolanticonceptivo oralModerada

    Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (etiqueta de Desogestrel y etinilestradiol, Precauciones)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralModerada

    The amount of both steroids should be considered in the choice of an oral contraceptive. (etiqueta de Diacetato de etinodiol y etinilestradiol, Advertencias)

  • DicicloverinaanticolinérgicoModerada

    Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (etiqueta de Dicicloverina, Interacciones medicamentosas)

  • DiclofenacoAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Diclofenaco, Advertencias y precauciones)

  • Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Diclofenaco y misoprostol, Advertencias y precauciones)

  • DiflunisalAINEModerada

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Diflunisal, Advertencias)

  • Digoxinaglucósido digitálicoModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Diltiazembloqueador de los canales de calcioModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Divalproato de sodio (valproato)anticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • DronedaronaantiarrítmicoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • DupilumabModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • EfavirenzantirretroviralModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Efavirenz, lamivudina y tenofovirantirretroviralModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Advertencias y precauciones)

  • Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Eritromicinaantibiótico macrólidoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • ErlotinibModerada

    Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (etiqueta de Erlotinib, Advertencias y precauciones)

  • EslicarbazepinaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • EstradiolestrógenoModerada

    Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (etiqueta de Estradiol, Precauciones)

  • Estradiol y dienogestanticonceptivo oralModerada

    Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (etiqueta de Estradiol y dienogest, Interacciones medicamentosas)

  • Estradiol y noretisteronaestrógenoModerada

    Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (etiqueta de Estradiol y noretisterona, Advertencias y precauciones)

  • Estrógenos conjugadosestrógenoModerada

    Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (etiqueta de Estrógenos conjugados, Precauciones)

  • Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (etiqueta de Estrógenos conjugados y bazedoxifeno, Advertencias y precauciones)

  • EtodolacoAINEModerada

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Etodolaco, Advertencias)

  • EtosuximidaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • EtravirinaantirretroviralModerada

    Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (etiqueta de Etravirina, Interacciones medicamentosas)

  • EverolimusinmunosupresorModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • FelbamatoanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)

  • Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (etiqueta de Fenilbutirato de glicerol, Interacciones medicamentosas)

  • Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (etiqueta de Fenilbutirato de sodio, Interacciones medicamentosas)

  • FenilefrinadescongestionanteModerada

    Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (etiqueta de Fenilefrina, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • FenobarbitalbarbitúricoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • FenoprofenoAINEModerada

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Fenoprofeno, Advertencias y precauciones)

  • FentaniloopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Fentanilo, Advertencias y precauciones)

  • Fentermina y topiramatoestimulante del SNCModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • FingolimodinmunosupresorModerada

    In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (etiqueta de Fingolimod, Advertencias y precauciones)

  • Fluconazolantifúngico azólicoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • FludrocortisonacorticosteroideModerada

    Although PULMICORT FLEXHALER may provide control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies. (etiqueta de Budesonida, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    Pregnancy As with other corticosteroids, flunisolide has been shown to be teratogenic and fetotoxic in rabbits and rats at oral doses of 40 and 200 mcg/kg/day, respectively (approximately 2 and 4 times, respectively, the maximum recommended daily intranasal dose in adults on a mg/m 2 basis). (etiqueta de Flunisolida, Precauciones)

  • FluocinonidacorticosteroideModerada

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (etiqueta de Fluocinonida, Advertencias y precauciones)

  • FlurbiprofenoAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (etiqueta de Flurbiprofeno, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • FosfenitoínaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • GabapentinaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • GlimepiridasulfonilureaModerada

    …medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (etiqueta de Glimepirida, Interacciones medicamentosas)

  • GlipizidasulfonilureaModerada

    …examples of medication that may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin,… (etiqueta de Glipizida, Interacciones medicamentosas)

  • HalobetasolcorticosteroideModerada

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (etiqueta de Halobetasol, Advertencias y precauciones)

  • HaloperidolantipsicóticoModerada

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (etiqueta de Haloperidol, Interacciones medicamentosas)

  • HidralazinavasodilatadorModerada

    Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (etiqueta de Hidralazina, Advertencias)

  • HidrocodonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona e ibuprofeno, Advertencias)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y clorfenamina, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y homatropina, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y paracetamol, Advertencias)

  • HidromorfonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidromorfona, Advertencias y precauciones)

  • IbandronatobisfosfonatoModerada

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (etiqueta de Ibandronato, Advertencias y precauciones)

  • IbuprofenoAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Ibuprofeno, Advertencias y precauciones)

  • Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Ibuprofeno y famotidina, Advertencias y precauciones)

  • Imatinibinhibidor de CYP3A4Moderada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • IndometacinaAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Indometacina, Advertencias y precauciones)

  • Insulina aspartainsulinaModerada

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (etiqueta de Insulina asparta, Interacciones medicamentosas)

  • Insulina degludecinsulinaModerada

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (etiqueta de Insulina degludec, Interacciones medicamentosas)

  • Insulina detemirinsulinaModerada

    Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (etiqueta de Insulina detemir, Interacciones medicamentosas)

  • Insulina glarginainsulinaModerada

    Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (etiqueta de Insulina glargina, Interacciones medicamentosas)

  • Insulina lisproinsulinaModerada

    Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (etiqueta de Insulina lispro, Interacciones medicamentosas)

  • IpratropioanticolinérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • Ipratropio y salbutamolanticolinérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • IsoniazidaantibióticoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Isoprenalina (isoproterenol)agonista beta-adrenérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • Itraconazolantifúngico azólicoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Ivacaftorinhibidor de CYP3A4Moderada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • IvermectinaModerada

    Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (etiqueta de Ivermectina, Advertencias)

  • KetoprofenoAINEModerada

    PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (etiqueta de Ketoprofeno, Advertencias y precauciones)

  • KetorolacoAINEModerada

    In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Ketorolaco, Advertencias y precauciones)

  • LacosamidaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • LamotriginaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • LenacapavirantirretroviralModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • LevetiracetamanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • LevofloxacinofluoroquinolonaModerada

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Levofloxacino, Advertencias y precauciones)

  • Levonorgestrel y etinilestradiolanticonceptivo oralModerada

    Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (etiqueta de Levonorgestrel y etinilestradiol, Interacciones medicamentosas)

  • LevorfanolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Levorfanol, Advertencias)

  • Levosalbutamolagonista beta-adrenérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • Levotiroxinahormona tiroideaModerada

    Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (etiqueta de Levotiroxina, Advertencias y precauciones)

  • Levotiroxina y liotironinahormona tiroideaModerada

    The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

  • Liotironinahormona tiroideaModerada

    Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency Thyroid hormone increases metabolic clearance of glucocorticoids. (etiqueta de Liotironina, Advertencias y precauciones)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAModerada

    Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (etiqueta de Lisinopril e hidroclorotiazida, Advertencias)

  • Lopinavir y ritonavirantirretroviralModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • MargetuximabModerada

    In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (etiqueta de Margetuximab, Advertencias y precauciones)

  • MedroxiprogesteronaprogestágenoModerada

    MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (etiqueta de Medroxiprogesterona, Advertencias y precauciones)

  • MegestrolprogestágenoModerada

    Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (etiqueta de Megestrol, Advertencias y precauciones)

  • MeloxicamAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Meloxicam, Advertencias y precauciones)

  • MepolizumabModerada

    Decrease corticosteroids gradually, if appropriate. (etiqueta de Mepolizumab, Advertencias y precauciones)

  • MesuximidaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • MetadonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Metadona, Advertencias y precauciones)

  • Metazolamidainhibidor de la anhidrasa carbónicaModerada

    Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (etiqueta de Metazolamida, Interacciones medicamentosas)

  • MetildopaantihipertensivoModerada

    If not, corticosteroids may be given and other causes of anemia should be considered. (etiqueta de Metildopa, Advertencias)

  • MetiltestosteronaandrógenoModerada

    Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etiqueta de Metiltestosterona, Advertencias)

  • MetiraponaModerada

    This can be corrected by giving appropriate doses of corticosteroids. (etiqueta de Metirapona, Advertencias y precauciones)

  • Metolazonadiurético tiazídicoModerada

    Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (etiqueta de Metolazona, Interacciones medicamentosas)

  • MetotrexatoinmunosupresorModerada

    NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (etiqueta de Metotrexato, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • MometasonacorticosteroideModerada

    Lung function (FEV 1 or PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral or other systemic corticosteroids. (etiqueta de Mometasona, Advertencias y precauciones)

  • Montelukastantagonista de los receptores de leucotrienosModerada

    Inhaled corticosteroid may be reduced gradually. (etiqueta de Montelukast, Advertencias y precauciones)

  • MorfinaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Morfina, Advertencias y precauciones)

  • MoxifloxacinofluoroquinolonaModerada

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Moxifloxacino, Advertencias y precauciones)

  • NabumetonaAINEModerada

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Nabumetona, Advertencias)

  • NalbufinaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Nalbufina, Advertencias)

  • Naltrexona y bupropiónantagonista opioideModerada

    …hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (etiqueta de Naltrexona y bupropión, Advertencias y precauciones)

  • NaproxenoAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Naproxeno, Advertencias y precauciones)

  • Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Naproxeno y esomeprazol, Advertencias y precauciones)

  • NatalizumabinmunosupresorModerada

    In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (etiqueta de Natalizumab, Advertencias y precauciones)

  • NateglinidameglitinidaModerada

    Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (etiqueta de Nateglinida, Interacciones medicamentosas)

  • NefazodonaantidepresivoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • NintedanibModerada

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (etiqueta de Nintedanib, Advertencias y precauciones)

  • Nirmatrelvir y ritonavirantiviralModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • OcrelizumabinmunosupresorModerada

    In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (etiqueta de Ocrelizumab, Advertencias y precauciones)

  • OfloxacinofluoroquinolonaModerada

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Ofloxacino, Advertencias)

  • OliceridinaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oliceridina, Advertencias y precauciones)

  • OmalizumabModerada

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (etiqueta de Omalizumab, Advertencias y precauciones)

  • OxaprozinaAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Oxaprozina, Advertencias y precauciones)

  • OxcarbazepinaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • OxicodonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oxicodona, Advertencias y precauciones)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oxicodona y paracetamol, Advertencias y precauciones)

  • OximorfonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oximorfona, Advertencias y precauciones)

  • Palbociclibinhibidor de CYP3A4Moderada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • PamidronatobisfosfonatoModerada

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

  • Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Paracetamol e ibuprofeno, Advertencias y precauciones)

  • Paracetamol y codeínaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Paracetamol y codeína, Advertencias)

  • PasireotidaModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

  • PenicilaminaModerada

    Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etiqueta de Penicilamina, Advertencias)

  • Pentazocina y naloxonaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Pentazocina y naloxona, Advertencias)

  • PerampanelanticonvulsivoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Petidina (meperidina)opioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Petidina (meperidina), Advertencias y precauciones)

  • Pioglitazona y glimepiridatiazolidinedionaModerada

    …medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (etiqueta de Pioglitazona y glimepirida, Interacciones medicamentosas)

  • PiroxicamAINEModerada

    Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Piroxicam, Advertencias y precauciones)

  • PonesimodinmunosupresorModerada

    Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (etiqueta de Ponesimod, Advertencias y precauciones)

  • Posaconazolantifúngico azólicoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • PregabalinaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • PrimidonaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • Prometazina y codeínaopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Prometazina y codeína, Advertencias y precauciones)

  • Propofoldepresor del SNCModerada

    The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (etiqueta de Propofol, Advertencias y precauciones)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • RifampicinaantibióticoModerada

    …Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (etiqueta de Rifampicina, Interacciones medicamentosas)

  • RifapentinaantibióticoModerada

    …Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (etiqueta de Rifapentina, Interacciones medicamentosas)

  • RisedronatobisfosfonatoModerada

    …the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etiqueta de Risedronato, Advertencias y precauciones)

  • RitonavirantirretroviralModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Rocuroniobloqueador neuromuscularModerada

    Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (etiqueta de Rocuronio, Advertencias y precauciones)

  • RufinamidaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • Salbutamolagonista beta-adrenérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • SalsalatoAINEModerada

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Salsalato, Advertencias)

  • SulindacoAINEModerada

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Sulindaco, Advertencias)

  • Sumatriptán y naproxenotriptánModerada

    Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

  • Suvorexantsedante-hipnóticoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Suxametonio (succinilcolina)bloqueador neuromuscularModerada

    The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (etiqueta de Suxametonio (succinilcolina), Interacciones medicamentosas)

  • Tabaco y tabaquismoTabaco y cannabisModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • TapentadolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tapentadol, Advertencias y precauciones)

  • TemozolomidaModerada

    Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

  • TemsirolimusModerada

    If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • TeofilinametilxantinaModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • Terbutalinaagonista beta-adrenérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • Teriparatidahormona tiroideaModerada

    Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (etiqueta de Teriparatida, Advertencias y precauciones)

  • TesamorelinaModerada

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (etiqueta de Tesamorelina, Interacciones medicamentosas)

  • TestosteronaandrógenoModerada

    Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (etiqueta de Testosterona, Advertencias y precauciones)

  • TiagabinaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • Ticagrelorantiagregante plaquetarioModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • TiotropioanticolinérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • TolmetinaAINEModerada

    Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Tolmetina, Advertencias)

  • TopiramatoanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • Torasemidadiurético de asaModerada

    Corticosteroids and ACTH: Increased risk of hypokalemia. (etiqueta de Torasemida, Interacciones medicamentosas)

  • TramadolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tramadol, Advertencias y precauciones)

  • Tramadol y paracetamolopioideModerada

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tramadol y paracetamol, Advertencias y precauciones)

  • TrastuzumabModerada

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioModerada

    Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (etiqueta de Triamtereno e hidroclorotiazida, Interacciones medicamentosas)

  • UmeclidinioanticolinérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • Verapamilobloqueador de los canales de calcioModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • Vibegrónagonista beta-adrenérgicoModerada

    Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (etiqueta de Budesonida, Advertencias y precauciones)

  • VigabatrinaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

  • Voriconazolantifúngico azólicoModerada

    Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (etiqueta de Budesonida, Advertencias y precauciones)

  • WarfarinaanticoagulanteModerada

    More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (etiqueta de Warfarina, Interacciones medicamentosas)

  • Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (etiqueta de Zenocutuzumab, Advertencias y precauciones)

  • ZonisamidaanticonvulsivoModerada

    Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida, Advertencias y precauciones)

Menciones leves (79)

  • AcarbosaantidiabéticoLeve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (etiqueta de Acarbosa, Interacciones medicamentosas)

  • Ácido bempedoicoinhibidor de OATP1B1Leve

    Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (etiqueta de Ácido bempedoico, Advertencias y precauciones)

  • Ácido etacrínicodiurético de asaLeve

    Care should also be exercised in patients receiving potassium-depleting steroids. (etiqueta de Ácido etacrínico, Advertencias)

  • If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (etiqueta de Alteplasa, Advertencias y precauciones)

  • AmikacinaaminoglucósidoLeve

    Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (etiqueta de Amikacina, Advertencias y precauciones)

  • Ampicilinaantibiótico del grupo de las penicilinasLeve

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (etiqueta de Ampicilina, Advertencias)

  • Anfetaminaestimulante del SNCLeve

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Anfetamina, Interacciones medicamentosas)

  • Anfetamina y dexanfetaminaestimulante del SNCLeve

    Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Anfetamina y dexanfetamina, Interacciones medicamentosas)

  • Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etiqueta de Bevacizumab, Advertencias y precauciones)

  • Corticosteroids, ACTH - Intensified electrolyte depletion, particularly hypokalemia. (etiqueta de Bisoprolol e hidroclorotiazida, Precauciones)

  • The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (etiqueta de Busulfano, Advertencias)

  • Calcitriolanálogo de la vitamina DLeve

    Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (etiqueta de Calcitriol, Interacciones medicamentosas)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Steroids or Adrenocorticotropic Hormone – Hypokalemia may develop during concomitant use of steroids or adrenocorticotropic hormone (ACTH). (etiqueta de Candesartán e hidroclorotiazida, Interacciones medicamentosas)

  • CefaclorcefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefaclor, Advertencias)

  • CefadroxilocefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefadroxilo, Advertencias y precauciones)

  • CefdinircefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefdinir, Advertencias)

  • CefotetáncefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefotetán, Advertencias)

  • CefprozilocefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefprozilo, Advertencias)

  • CeftazidimacefalosporinaLeve

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Ceftazidima, Advertencias)

  • CeftriaxonacefalosporinaLeve

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (etiqueta de Ceftriaxona, Advertencias y precauciones)

  • ClofarabinaantimetabolitoLeve

    The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (etiqueta de Clofarabina, Advertencias y precauciones)

  • Clomifenomodulador selectivo de los receptores de estrógenosLeve

    Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (etiqueta de Clomifeno, Advertencias)

  • Clorotiazidadiurético tiazídicoLeve

    Corticosteroids, ACTH - intensified electrolyte depletion, particularly hypokalemia. (etiqueta de Clorotiazida, Interacciones medicamentosas)

  • Clotrimazolantifúngico azólicoLeve

    When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with PULMICORT FLEXHALER continues, but at times, therapy with PULMICORT FLEXHALER may need to be interrupted. (etiqueta de Budesonida, Advertencias y precauciones)

  • The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (etiqueta de Corticotropina, Advertencias y precauciones)

  • Dapagliflozina y metforminainhibidor de SGLT2Leve

    These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Dapagliflozina y metformina, Interacciones medicamentosas)

  • Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

  • Dexanfetaminaestimulante del SNCLeve

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Dexanfetamina, Interacciones medicamentosas)

  • Droperidolantagonista de la dopaminaLeve

    These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (etiqueta de Droperidol, Interacciones medicamentosas)

  • Drospirenona y etinilestradiolanticonceptivo oralLeve

    Steroid hormones may be poorly metabolized in patients with impaired liver function. (etiqueta de Drospirenona y etinilestradiol, Advertencias y precauciones)

  • Econazolantifúngico azólicoLeve

    When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with PULMICORT FLEXHALER continues, but at times, therapy with PULMICORT FLEXHALER may need to be interrupted. (etiqueta de Budesonida, Advertencias y precauciones)

  • Empagliflozina y metforminainhibidor de SGLT2Leve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Empagliflozina y metformina, Interacciones medicamentosas)

  • Enalapril e hidroclorotiazidainhibidor de la ECALeve

    Corticosteroids, ACTH Intensified electrolyte depletion, particularly hypokalemia. (etiqueta de Enalapril e hidroclorotiazida, Interacciones medicamentosas)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaLeve

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia, may occur. (etiqueta de Espironolactona e hidroclorotiazida, Interacciones medicamentosas)

  • Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (etiqueta de Etonogestrel y etinilestradiol, Interacciones medicamentosas)

  • FludarabinaantimetabolitoLeve

    Steroids may or may not be effective in controlling these hemolytic episodes. (etiqueta de Fludarabina, Advertencias y precauciones)

  • FluoxetinaISRSLeve

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Fluoxetina, Advertencias y precauciones)

  • GlibenclamidasulfonilureaLeve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Glibenclamida, Interacciones medicamentosas)

  • Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Glibenclamida y metformina, Interacciones medicamentosas)

  • Glipizida y metforminasulfonilureaLeve

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Glipizida y metformina, Precauciones)

  • In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

  • GuselkumabinmunosupresorLeve

    TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (etiqueta de Guselkumab, Advertencias y precauciones)

  • Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (etiqueta de Insulina regular (humana), Interacciones medicamentosas)

  • Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (etiqueta de Lenalidomida, Advertencias y precauciones)

  • Linagliptina y metforminainhibidor de la DPP-4Leve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Linagliptina y metformina, Interacciones medicamentosas)

  • The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (etiqueta de Melfalán, Advertencias)

  • Metanfetaminaestimulante del SNCLeve

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etiqueta de Metanfetamina, Interacciones medicamentosas)

  • MetforminabiguanidaLeve

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Metformina, Interacciones medicamentosas)

  • Metimazolfármaco antitiroideoLeve

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etiqueta de Metimazol, Advertencias)

  • MetohexitalbarbitúricoLeve

    Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (etiqueta de Metohexital, Advertencias)

  • Miconazolantifúngico azólicoLeve

    When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with PULMICORT FLEXHALER continues, but at times, therapy with PULMICORT FLEXHALER may need to be interrupted. (etiqueta de Budesonida, Advertencias y precauciones)

  • Midodrinaagonista alfa-adrenérgicoLeve

    Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (etiqueta de Midodrina, Interacciones medicamentosas)

  • Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

  • Naltrexonaantagonista opioideLeve

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (etiqueta de Naltrexona, Advertencias y precauciones)

  • Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (etiqueta de Norelgestromina y etinilestradiol, Interacciones medicamentosas)

  • Noretisterona y etinilestradiolanticonceptivo oralLeve

    Steroid hormones may be poorly metabolized in patients with impaired liver function. (etiqueta de Noretisterona y etinilestradiol, Advertencias y precauciones)

  • Norgestimato y etinilestradiolanticonceptivo oralLeve

    Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (etiqueta de Norgestimato y etinilestradiol, Interacciones medicamentosas)

  • Norgestrel y etinilestradiolanticonceptivo oralLeve

    Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (etiqueta de Norgestrel y etinilestradiol, Precauciones)

  • Olanzapina y fluoxetinaantipsicóticoLeve

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Olanzapina y fluoxetina, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (etiqueta de Olmesartán e hidroclorotiazida, Interacciones medicamentosas)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Leve

    Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (etiqueta de Olmesartán, amlodipino e hidroclorotiazida, Interacciones medicamentosas)

  • Oxacilinaantibiótico del grupo de las penicilinasLeve

    If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (etiqueta de Oxacilina, Advertencias)

  • Penicilina Gantibiótico del grupo de las penicilinasLeve

    Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (etiqueta de Penicilina G, Advertencias)

  • Penicilina Vantibiótico del grupo de las penicilinasLeve

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (etiqueta de Penicilina V, Advertencias)

  • Pioglitazona y metforminatiazolidinedionaLeve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Pioglitazona y metformina, Interacciones medicamentosas)

  • Propiltiouracilofármaco antitiroideoLeve

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etiqueta de Propiltiouracilo, Advertencias)

  • QuininaantipalúdicoLeve

    Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (etiqueta de Quinina, Interacciones medicamentosas)

  • Raloxifenomodulador selectivo de los receptores de estrógenosLeve

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Raloxifeno, Interacciones medicamentosas)

  • RepaglinidameglitinidaLeve

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (etiqueta de Repaglinida, Interacciones medicamentosas)

  • RituximabinmunosupresorLeve

    Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etiqueta de Rituximab, Advertencias y precauciones)

  • Saxagliptina y metforminainhibidor de la DPP-4Leve

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Saxagliptina y metformina, Interacciones medicamentosas)

  • Sitagliptina y metforminainhibidor de la DPP-4Leve

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Sitagliptina y metformina, Interacciones medicamentosas)

  • If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (etiqueta de Tenecteplasa, Advertencias y precauciones)

  • TobramicinaaminoglucósidoLeve

    In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

  • UstekinumabinmunosupresorLeve

    Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (etiqueta de Ustekinumab, Advertencias y precauciones)

  • Vitamina DVitaminas y mineralesLeve

    Los corticosteroides como la prednisona reducen la absorción de calcio y alteran el metabolismo de la vitamina D, lo que contribuye a la pérdida de masa ósea. (NIH Office of Dietary Supplements, Vitamin D)

  • Zafirlukastantagonista de los receptores de leucotrienosLeve

    An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or non-corticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (etiqueta de Budesonida, Advertencias y precauciones)

  • Zileutóninhibidor de CYP1A2Leve

    An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or non-corticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (etiqueta de Budesonida, Advertencias y precauciones)

  • ZiprasidonaantipsicóticoLeve

    Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Ziprasidona, Advertencias y precauciones)

Compruebe Budesonida frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.